IN8BIO, Inc. SEC filings INAB
IN8BIO, Inc. has 412 filings in SEC EDGAR's recent list, going back to May 22, 2018. Its latest annual report, Form ARS, was filed on Mar 26, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | May 19, 2026 | — |
| CORRESP | Letter to the SEC | May 15, 2026 | — |
| EFFECT | Filing | Jan 28, 2026 | — |
| UPLOAD | Letter from the SEC | Jan 27, 2026 | — |
| CORRESP | Letter to the SEC | Jan 26, 2026 | — |
| D | Filing | Dec 30, 2025 | — |
| DEFR14A | Filing | Apr 29, 2025 | — |
| EFFECT | Filing | Nov 12, 2024 | — |
| CORRESP | Letter to the SEC | Nov 8, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 7, 2024 | — |
| D | Filing | Oct 15, 2024 | — |
| EFFECT | Filing | Jan 18, 2024 | — |
| CORRESP | Letter to the SEC | Jan 16, 2024 | — |
| UPLOAD | Letter from the SEC | Jan 16, 2024 | — |
| D | Filing | Dec 28, 2023 | — |
| EFFECT | Filing | Nov 21, 2022 | — |
| CORRESP | Letter to the SEC | Nov 17, 2022 | — |
| UPLOAD | Letter from the SEC | Nov 17, 2022 | — |
| POS EX | Filing | Aug 12, 2022 | — |
| EFFECT | Filing | Aug 11, 2022 | — |
| CORRESP | Letter to the SEC | Aug 8, 2022 | — |
| CORRESP | Letter to the SEC | Aug 8, 2022 | — |
| UPLOAD | Letter from the SEC | Jul 26, 2022 | — |
| DRS | Filing | Jul 20, 2022 | — |
| EFFECT | Filing | Jul 29, 2021 | — |
| CORRESP | Letter to the SEC | Jul 26, 2021 | — |
| CORRESP | Letter to the SEC | Jul 26, 2021 | — |
| CORRESP | Letter to the SEC | May 7, 2021 | — |
| UPLOAD | Letter from the SEC | Apr 15, 2021 | — |
| CORRESP | Letter to the SEC | Nov 16, 2020 | — |
| CORRESP | Letter to the SEC | Nov 16, 2020 | — |
| CERT | Filing | Nov 10, 2020 | — |
| 8-A12B | Form 8-a12b | Nov 10, 2020 | — |
| CORRESP | Letter to the SEC | Nov 9, 2020 | — |
| CORRESP | Letter to the SEC | Nov 9, 2020 | — |
| SEC STAFF LETTER | Filing | Nov 6, 2020 | — |
| CORRESP | Letter to the SEC | Oct 27, 2020 | — |
| DRSLTR | Filing | Oct 9, 2020 | — |
| DRS/A | Filing | Oct 9, 2020 | — |
| UPLOAD | Letter from the SEC | Oct 7, 2020 | — |
| SEC STAFF LETTER | Filing | Oct 1, 2020 | — |
| DRS | Filing | Sep 10, 2020 | — |
| D/A | Filing | Sep 4, 2020 | — |
| D/A | Filing | Sep 20, 2018 | — |
| D | Filing | May 22, 2018 | — |
Showing 45 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- INAB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1740279
- Former names
- Incysus Therapeutics, Inc. (until Sep 20, 2018)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.